natgillin/translations-raw huggingface dataset:
If any of these affects you severely, tell your doctor. 
Če imate hudo obliko katerega od zgoraj navedenih učinkov, obvestite zdravnika.
NAME OF MEDICINAL PRODUCT Imatinib Accord 100 mg film-coated tablets Imatinib Accord 400 mg film-coated tablets 
Imatinib Accord 100 mg filmsko obložene tablete Imatinib Accord 400 mg filmsko obložene tablete
• Painful and/or blistering skin lesions. 
• boleče spremembe na koži z ali brez nastanka mehurjev.
Severe elevation of transaminases (< 5%) or bilirubin (< 1%) was seen in CML patients and was usually managed with dose reduction or interruption (the median duration of these episodes was approximately one week). 
Navadno so to urejali z zmanjšanjem odmerka ali s prekinitvijo zdravljenja (povprečno trajanje teh epizod je bilo približno en teden).
WBC < 10 x 109/l, platelet < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement 
9/l, mielociti+metamielociti < 5 % v krvi, brez blastov in promielocitov v krvi, bazofilci < 20 %, brez prizadetosti zunaj kostnega mozga] in v študijah 0102 in 0109 [ANC 1,5 x 10
Total bilirubin: > 3-10 ULN AST: any ULN = upper limit of normal for the institution AST = aspartate aminotransferase 
IULN = zgornja meja normalnih vrednosti, specifična za ustanovo
Brownish orange, oval shaped, biconvex, film-coated tablets, debossed on one side with ‘IM' and ‘T2' on either side of breakline and plain on the other side. 
Rjavooranžne, ovalne, bikonveksne filmsko obložene tablete z vtisnjenima oznakama “IM” in “T2” na vsaki strani zareze na eni strani tablete in brez oznake na drugi strani.
ARA-C (3 g/m2/dose q 12 h x 4, IV): days 2 and 3 
ARA-C (3 g/m2, vsakih 12 ur, i.v.
Daunorubicin 45 mg/ m2 i.v., days 6-7, 13-14 
VCR 2 mg i.v., 6., 13., 20. dan; daunorubicin 45 mg/m2 i.v., 6.-7., 13.-14. dan indukcijsko zdravljenje II
G-CSF (5 μg/kg, SC): days 27-36 or until ANC > 1500 post nadir ARA-C (3 g/m2, q12h, IV): days 43, 44 
): 22.-26. dan G-CSF (5 μg/kg, s.c.): 27.-36. dan oziroma do ANC > 1500 po doseženem najnižjem številu
Rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, dermatitis exfoliative, onychoclasis, folliculitis, petechiae, psoriasis, purpura, skin hyperpigmentation, bullous eruptions 
hipotenzija, Raynaudov fenomen pogostnost neznana tromboza/embolija* Bolezni dihal, prsnega koša in mediastinalnega prostora pogosti dispneja, krvavitev iz nosu, kašelj občasni plevralni izliv5, bolečine v žrelu in grlu, vnetje žrela redki plevritična bolečina, pljučna fibroza, pljučna hipertenzija, pljučna krvavitev pogostnost neznana akutna respiratorna odpoved11*, intersticijska pljučna bolezen* Bolezni prebavil zelo pogosti navzea, driska, bruhanje, dispepsija, bolečine v trebuhu6
You should take 
• izpuščaj,
In CML, cytopenias, particularly neutropenia and thrombocytopenia, have been a consistent finding in all studies, with the suggestion of a higher frequency at high doses ≥ 750 mg (phase I study). 
Podatki kažejo, da so lahko citopenije pogostejše pri velikih odmerkih  750 mg (študija prve faze),
When and how to take Imatinib Accord 
Kdaj in kako jemati zdravilo Imatinib Accord - Zdravilo Imatinib Accord vzemite z obrokom hrane.
Manufacturer 
ZDRAVILA
Common (may affect up to 1 in 10 people) 
Pogosti neželeni učinki (pojavijo se lahko pri največ 1 od 10 bolnikov)
If you are being treated for MDS/MPD The starting dose is 400 mg to be taken as 4 tablets of 100 mg or one tablet of 400 mg once a day. 
Začetni odmerek je 400 mg, kar vzamete kot 4 tablete po 100 mg ali eno tableto po 400 mg enkrat na dan.
DEX 10 mg/ m2 oral, days 1-5; CP 200 mg/ m2 i.v., days 3-5; MTX 15mg intrathecal, day 1 
DEX 10 mg/m2 peroralno, 1.-5. dan; CP 200 mg/m2 i.v., 3.-5. dan;
Partial Haematological response criteria (all responses to be confirmed after ≥ 4 weeks): CHR: Study 0110 [WBC < 10 x 109/l, platelets < 450 x 109/l, myelocyte+metamyelocyte < 5% in blood, no blasts and promyelocytes in blood, basophils < 20%, no extramedullary involvement] and in studies 0102 and 0109 [ANC ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, no blood blasts, BM blasts < 5% and no extramedullary disease] NEL Same criteria as for CHR but ANC ≥ 1 x 109/l and platelets ≥ 20 x 109/l (0102 and 0109 only) RTC < 15% blasts BM and PB, < 30% blasts+promyelocytes in BM and PB, < 20% basophils in PB, no extramedullary disease other than spleen and liver (only for 0102 and 0109). 
RTC < 15 % blastov v BM in PB, < 30 % blastov+promielocitov v BM in PB, < 20 % bazofilcev v PB, brez bolezni zunaj kostnega mozga, razen v vranici in jetrih (samo za 0102 in 0109).
Methotrexate (5 g/m2 over 24 hours, IV): days 1 and 15 Leucovorin (75 mg/m2 at hour 36, IV; 15 mg/m2 IV or PO q6h x 
): 1. in 15. dan levkovorin (75 mg/m2 36 ur po začetku, i.v.
NAME OF THE MEDICINAL PRODUCT Imatinib Accord 100 mg film-coated tablets imatinib 
Imatinib Accord 100 mg filmsko obložene tablete imatinib
Increased intracranial pressure, convulsions, optic neuritis 
Prilagajanje odmerkov zaradi nevtropenije in trombocitopenije:
If your daily dose is 800 mg (8 tablets of 100 mg or 2 tablets of 400 mg). 
Če je vaš dnevni odmerek 800 mg (8 tablet po 100 mg ali 2 tableti po 400 mg), morate vzeti 4 tablete po 100 mg ali 1 tableto po 400 mg zjutraj in 4 tablete po 100 mg ali 1 tableto po 400 mg zvečer.
Methotrexate (20 mg/m2/week, PO): days 1, 8, 15, 22, 29, 36, 43, 50 
): 1. in 29. dan DEX (6 mg/m2/dan, peroralno): 1.-5. dan in 29.-33. dan 6-MP (75 mg/m2/dan, peroralno): 1.-56. dan metotreksat (20 mg/m2/teden, peroralno): 1., 8., 15., 22., 29., 36., 43. in 50. dan
DAUN (45 mg/m2/day bolus, IV): days 1 and 2 
):1., 8. in 15. dan DAUN (45 mg/m2/dan bolus, i.v.
Clinical studies in chronic myeloid leukaemia 
Preglednica 3 Odziv pri odraslih bolnikih s KML v kliničnih študijah
Muscular weakness, arthritis, rhabdomyolysis/myopathy 
Taka zdravila so karbamazepin, okskarbazepin in fenitoin.
Prednisolone 200 mg oral, 5 days per month for 13 months All treatment regimens include administration of steroids for CNS prophylaxis. 
prednizolon 200 mg peroralno, 5 dni na mesec v obdobju 13 mesecev
NAME OF THE MEDICINAL PRODUCT Imatinib Accord 400 mg film-coated tablets imatinib 
Imatinib Accord 400 mg filmsko obložene tablete imatinib
STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 100 mg imatinib (as mesilate) 
NAVEDBA ENE ALI VEČ UČINKOVIN Ena filmsko obložena tableta vsebuje 100 mg imatiniba (v obliki mesilata).
Leucovorin (75 mg/m2 at hour 36, IV; 15 mg/m2 IV or PO q6h x 6 doses)iii: Days 2 and 3 
zdravljenje (prilagojeno na starost): 1. dan ARA-C (3 g/m2/odmerek vsakih 12 ur x 4, i.v.):2.
Haematological response criteria (all responses to be confirmed after ≥ 4 weeks): 
1 Kriteriji hematološkega odziva (vsi odzivi morajo biti potrjeni po 4 tednih): CHR študija 0110 [WBC < 10 x 10
On 16 November 2016, Gedeon Richter Plc officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Efgratin, for reducing neutropenia. 
Družba Gedeon Richter Plc je 16. novembra 2016 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za pridobitev dovoljenja za promet z zdravilom Efgratin, namenjenim zmanjševanju nevtropenije.
Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim) EMA/822770/2016 
Umik vloge za pridobitev dovoljenja za promet z zdravilom Efgratin (pegfilgrastim) EMA/822770/2016
This means that Efgratin was intended to be highly similar to a biological medicine (the ‘reference medicine') already authorised in the European Union called Neulasta. 
To pomeni, da naj bi bilo zelo podobno biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v Evropski uniji, in sicer zdravilu Neulasta.
A further study in patients receiving cancer medicines compared the safety and effectiveness of Efgratin and Neulasta. 
V drugi študiji pri bolnikih, ki so prejemali zdravila za zdravljenje raka, so primerjali varnost in učinkovitost zdravil Efgratin in Neulasta.
The company informed the CHMP that there are no ongoing clinical trials or compassionate-use programmes for Efgratin. 
Družba je odbor CHMP obvestila, da trenutno ne potekajo klinična preskušanja ali programi sočutne uporabe zdravila Efgratin.
Withdrawal of the marketing authorisation application for Efgratin (pegfilgrastim) 
Umik vloge za pridobitev dovoljenja za promet z zdravilom Efgratin (pegfilgrastim)
The company presented results of studies in healthy people designed to show that Efgratin is highly similar to its reference medicine Neulasta in terms of chemical structure, purity, the way it works and how the body handles the medicine. 
Družba je predstavila rezultate študij pri zdravih ljudeh, ki naj bi pokazale, da je zdravilo Efgratin po kemijski strukturi, čistosti, načinu delovanja in tem, kako ga telo presnavlja, zelo podobno referenčnemu zdravilu Neulasta.
Efgratin was developed as a ‘biosimilar' medicine. 
Zdravilo Efgratin je bilo razvito kot „podobno biološko zdravilo“.
The active substance in Efgratin, pegfilgrastim, consists of filgrastim that has been 'pegylated' (attached to a chemical called polyethylene glycol). 
Zdravilna učinkovina v zdravilu Efgratin, pegfilgrastim, je sestavljena iz filgrastima, ki je bil pegiliran (nanj je bila pritrjena kemična snov, imenovana polietilenglikol).
Efgratin is a medicine that contains the active substance pegfilgrastim, which stimulates the production of neutrophils (a type of white blood cell that fights infections). 
Efgratin je zdravilo, ki vsebuje zdravilno učinkovino pegfilgrastim, ki spodbuja nastajanje nevtrofilcev (vrste belih krvnih celic, ki se borijo proti okužbam).
Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not demonstrated that Efgratin is highly similar to Neulasta. 
Zato je odbor CHMP ob umiku vloge menil, da družba ni dokazala, da je zdravilo Efgratin zelo podobno zdravilu Neulasta.
What was Efgratin expected to be used for? 
Za kaj naj bi se zdravilo Efgratin uporabljalo?
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Efgratin could not have been approved for reducing neutropenia. 
Odbor CHMP je na podlagi pregleda podatkov in odgovorov družbe na sezname vprašanj, ki jih je zastavil, ob umiku vloge izrazil določene zadržke in je začasno menil, da zdravila Efgratin ni mogoče odobriti za zmanjševanje nevtropenije.
Efgratin was to be used in cancer patients to reduce neutropenia (low levels of neutrophils). 
Zdravilo Efgratin naj bi se uporabljajo pri rakavih bolnikih za zmanjševanje nevtropenije (nizkih ravni nevtrofilcev).
How does Efgratin work? 
Kako zdravilo Efgratin deluje?
The CHMP was concerned that study results had not shown that Efgratin was handled by the body in the same way as the reference medicine Neulasta. 
Izrazil je zaskrbljenost, da rezultati študije niso dokazali, da telo zdravilo Efgratin presnavlja na enak način kot referenčno zdravilo Neulasta.
What is Efgratin? 
Kaj je zdravilo Efgratin?
Efgratin was to be used to reduce the duration of neutropenia and the occurrence of febrile neutropenia (neutropenia with fever). 
Zdravilo Efgratin naj bi se uporabljalo za skrajšanje nevtropenije ter zmanjšanje pojavljanja febrilne nevtropenije (nevtropenije s povišano telesno temperaturo).
‘Metastatic' means that the cancer has spread to other parts of the body. 
„Metastatski“ pomeni, da se je rak razširil na druge dele telesa;
The European Commission granted a marketing authorisation valid throughout the European Union for Abraxane on 11 January 2008. 
Evropska komisija je dovoljenje za promet z zdravilom Abraxane, veljavno po vsej Evropski uniji, izdala 11. januarja 2008.
The full EPAR for Abraxane can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Abraxane je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
It should not be interchanged with other medicines containing paclitaxel. 
Ne sme se zamenjevati z drugimi zdravili, ki vsebujejo paklitaksel.
What measures are being taken to ensure the safe and effective use of Abraxane? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Abraxane?
This document is a summary of the European Public Assessment Report (EPAR) for Abraxane. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Abraxane.
For additional information, see the summary of product characteristics (also part of the EPAR). 
Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
Paclitaxel has been available as a cancer medicine since 1993. 
Paklitaksel je kot zdravilo proti raku na voljo od leta 1993.
A response was defined as the patient's main tumours disappearing or shrinking in size by at least 30%. 
Odziv je bil opredeljen kot popolno izginotje ali zmanjšanje glavnih tumorjev bolnice za najmanj 30 %.
The recommended dose is 125 mg per square metre of body surface area once a day on days 1, 8 and 15 of each cycle. 
Priporočeni odmerek je 125 mg na kvadratni meter telesne površine enkrat na dan na 1., 8. in 15. dan vsakega cikla.
The Committee decided that Abraxane's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je zaključil, da so koristi zdravila Abraxane večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The main measure of effectiveness was the percentage of patients who responded to treatment. 
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se odzvali na zdravljenje.
The most common important side effects with Abraxane (seen in more than 1 patient in 10) are neutropenia (low levels of neutrophils, a type of white blood cells), gastrointestinal disorders (disorders of the digestive system), peripheral neuropathy (nerve damage including damage to the nerves in the hand and feet), arthralgia (joint pain) and myalgia (muscle pain). 
Najpogostejši neželeni učinki zdravila Abraxane (opaženi pri več kot 1 bolniku od 10) so nevtropenija (nizka raven nevtrofilcev, tj. vrste belih krvničk), obolenja prebavil (obolenja prebavnega sistema), periferna nevropatija (poškodba živčevja, vključno s poškodbami živčevja dlani in stopal), artralgija (bolečine v sklepih) in mialgija (bolečine v mišicah).
Abraxane is used to treat the following cancers in adults: 
Zdravilo Abraxane se uporablja za zdravljenje naslednjih vrst raka pri odraslih:
Other information about Abraxane 
Druge informacije o zdravilu Abraxane
For more information about treatment with Abraxane, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Abraxane preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Paclitaxel blocks a stage of cell division in which the cell's internal ‘skeleton' is dismantled to allow the cell to divide. 
Paklitaksel prepreči fazo celične delitve, v kateri se notranji „skelet“ celice običajno razgradi, kar ji omogoči delitev.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Abraxane. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The recommended dose is 260 mg per square metre of body surface area (calculated using the patient's height and weight). 
Priporočeni odmerek je 260 mg na kvadratni meter telesne površine (izračunane na podlagi telesne višine in mase bolnika).
What benefit has Abraxane shown during the studies? 
Kakšne koristi je zdravilo Abraxane izkazalo med študijami?
Abraxane also affects non-cancer cells such as blood and nerve cells, which can cause side effects. 
Zdravilo Abraxane učinkuje tudi na nerakave celice, kot so krvne in živčne celice, kar lahko povzroči neželene učinke.
The main measure of effectiveness was the number of patients who ‘responded' after at least five weeks of treatment. 
Glavno merilo učinkovitosti je bilo število bolnic, ki so se odzvale na zdravljenje po najmanj petih tednih zdravljenja.
It contains the active substance paclitaxel attached to a human protein called albumin. 
Vsebuje zdravilno učinkovino paklitaksel, ki se veže na človeško beljakovino, imenovano albumin.
Overall, in the main study, 31% of the women receiving Abraxane responded to treatment (72 out of 229), compared with 16% of the women receiving conventional paclitaxel-containing medicines (37 out of 225). 
Skupno se je v glavni študiji na zdravljenje odzvalo 31 % (72 od 229) žensk, ki so prejemale zdravilo Abraxane, v primerjavi s 16 % (37 od 225) žensk, ki so prejemale standardna zdravila, ki vsebujejo paklitaksel.
The main measure of effectiveness was how long patients lived. 
Glavno merilo učinkovitosti je bil čas preživetja bolnikov.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abraxane, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
A risk management plan has been developed to ensure that Abraxane is used as safely and effectively as possible. 
Za zagotovitev čim varnejše uporabe zdravila Abraxane je bil pripravljen načrt obvladovanja tveganj.
For metastatic breast cancer, Abraxane has been studied in one main study involving 460 women, around three-quarters of whom had received an anthracycline in the past. 
Pri metastatskem raku dojke so zdravilo Abraxane proučevali v eni glavni študiji, v katero je bilo vključenih 460 žensk, od katerih jih je približno tri četrtine v preteklosti prejemalo enega od antraciklinov.
What is the risk associated with Abraxane? 
Kakšna tveganja so povezana z zdravilom Abraxane?
Therefore, the company withdrew its application for the use of Abraxane as firstline treatment during the assessment of the medicine. 
Zato je družba med vrednotenjem zdravila Abraxane umaknila vlogo za njegovo uporabo kot zdravilo prve izbire.
Abraxane must not be used in patients who are breast-feeding or who have low levels of neutrophils in the blood before starting treatment. 
Zdravila Abraxane ne smejo uporabljati bolnice, ki dojijo, ali bolniki z nizkimi ravnmi nevtrofilcev pred začetkom zdravljenja.
• metastatic breast cancer, when the first treatment has stopped working and standard treatment including an ‘anthracycline' (another type of cancer medicine) is not suitable. 
• metastatskega raka dojk, kadar je prvotno zdravljenje prenehalo delovati, standardno zdravljenje, ki vključuje antracikline (drugo vrsto zdravil proti raku), pa ni primerno.
In non-small cell lung cancer, treatment is carried out in 3-week cycles with Abraxane given on days 1, 8 and 15 of each cycle and carboplatin given on day 1 immediately after Abraxane. 
Pri nedrobnoceličnem pljučnem raku se zdravljenje izvaja v tritedenskih ciklih zdravljenja, in sicer se zdravilo Abraxane daje na 1., 8. in 15. dan vsakega cikla, karboplatin pa na 1. dan cikla takoj po infundiranju zdravila Abraxane.
The recommended dose of Abraxane is 100 mg per square metre of body surface area. 
Priporočeni odmerek zdravila Abraxane je 100 mg na kvadratni meter telesne površine.
Around half of the patients in the study had already received treatments for their cancer after it had become metastatic. 
Približno polovica bolnic v študiji je pred tem že bila zdravljena zaradi raka, ki se je razširil na druge dele telesa.
Why has Abraxane been approved? 
Zakaj je bilo zdravilo Abraxane odobreno?
Immediately after giving Abraxane gemcitabine should be given at a dose of 1000 mg per square metre of body surface area. 
Takoj po dajanju zdravila Abraxane mora bolnik prejeti gemcitabin v odmerku 1 000 mg na kvadratni meter telesne površine.
Abraxane should only be given under the supervision of a specialist cancer doctor in units that are specialised in giving ‘cytotoxic' (cell-killing) medicines. 
Zdravilo Abraxane se lahko daje samo pod nadzorom zdravnika specialista za rakava obolenja na oddelkih, ki so specializirani za dajanje citotoksičnih zdravil (zdravil, ki uničujejo celice).
The CHMP noted that Abraxane was more effective than conventional paclitaxel-containing medicines in patients with metastatic breast cancer whose first treatment had stopped working, and that, unlike other paclitaxel-containing medicines, patients to be treated with Abraxane do not need pre-treatment with other medicines to prevent hypersensitivity reactions. 
CHMP je menil, da je bilo zdravilo Abraxane pri bolnicah z metastatskih rakom dojke, pri katerih je prvotno zdravljenje prenehalo delovati, učinkovitejše od standardnih zdravil, ki vsebujejo paklitaksel, in da pri dajanju zdravila Abraxane za razliko od drugih zdravil, ki vsebujejo paklitaksel, predhodno zdravljenje z drugimi zdravili za preprečevanje preobčutljivostnih reakcij ni potrebno.
For metastatic adenocarcinoma of the pancreas, Abraxane was studied in one main study involving 861 patients who received either Abraxane in combination with gemcitabine or gemcitabine alone. 
Pri metastatskem adenokarcinomu trebušne slinavke so zdravilo Abraxane proučevali v eni glavni študiji, ki je zajela 861 bolnikov in v kateri so bolniki prejemali bodisi zdravilo Abraxane v kombinaciji z gemcitabinom bodisi samo gemcitabin.
The active substance in Abraxane, paclitaxel, belongs to the group of cancer medicines known as the ‘taxanes'. 
Zdravilna učinkovina zdravila Abraxane, paklitaksel, spada v skupino zdravil proti raku, imenovanih taksani.
In Abraxane, unlike conventional paclitaxel-containing medicines, the paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles'. 
Za razliko od drugih zdravil, ki vsebujejo paklitaksel, je ta učinkovina v zdravilu Abraxane vezana na človeško beljakovino albumin v drobnih delcih, imenovanih nanodelci.
When looking only at the patients who were receiving their first treatment for metastatic breast cancer, there was no difference between the medicines in terms of measures of effectiveness such as the time until the disease got worse and survival. 
Pri proučevanju bolnic, ki so se zaradi metastatskega raka dojk zdravile prvič, pri merilih učinkovitosti, kot sta čas do poslabšanja bolezni in čas preživetja, razlik med zdravili ni bilo.
• metastatic adenocarcinoma of the pancreas, as a first treatment in combination with another cancer medicine, gemcitabine. 
• metastatskega adenokarcinoma trebušne slinavke, pri katerem se uporablja kot zdravilo prve izbire v kombinaciji z drugim zdravilom za zdravljenje raka, tj. gemcitabinom;
In addition, Abraxane given in combination with gemcitabine was shown to improve survival in patients with metastatic adenocarcinoma of the pancreas compared with treatment with gemcitabine alone and was effective in combination with carboplatin in the treatment non-small cell lung cancer. 
Poleg tega je zdravilo Abraxane v kombinaciji z gemcitabinom za razliko od zdravljenja zgolj z gemcitabinom izboljšalo čas preživetja pri bolnikih z metastatskih adenokarcinomom trebušne slinavke in bilo učinkovito v kombinaciji s karboplatinom pri zdravljenju nedrobnoceličnega raka pljuč.
Patients survived for around 8.5 months on treatment with the combination of Abraxane and gemcitabine, compared with 6.7 months on gemcitabine alone. 
Bolniki so ob zdravljenju s kombinacijo zdravila Abraxane in gemcitabina živeli približno 8,5 meseca v primerjavi s 6,7 meseca v skupini bolnikov, ki so prejemali samo gemcitabin.